Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
The global Japanese Encephalitis (JE) Vaccine market size was valued at USD 499.34 Million in 2022 and will reach USD 658.15 Million in 2028, with a CAGR of 4.71% during 2022-2028.
Japanese encephalitis (JE) is the leading cause of viral encephalitis in many Asian countries. JE virus is a flavivirus associated with dengue, yellow fever and West Nile virus and is transmitted by mosquitoes, causing infection. The virus is transmitted in an enzootic cycle (enzootic cycle) between mosquitoes, pigs, and/or waterfowl. Humans become infected when they are bitten by an infected mosquito. The disease occurs mainly in rural and peri-urban areas.
Japanese encephalitis vaccine is a vaccine that protects against Japanese encephalitis.
Market Opportunities
Since the first discovery of JE vaccines in the 1930s, the JE vaccine industry has evolved from the original vaccine to live attenuated and inactivated vaccines as vaccine technology has advanced. Currently, polyvalent conjugate and combination vaccines are the main technological trends.
Moreover, in addition to the rising awareness of the disease, the increase in travel and tourism is one of the key factors contributing to the growth of the industry. The tropics are the most lucrative market due to high prevalence of JE in the tropics, expansion of government-led national immunization programs, growth in R&D investments, entry of new vaccine manufacturers from countries such as India and China, increase in tourist arrivals, medical tourism, etc. Moreover, increase in pig farms, poultry and mosquito infestation in Asia Pacific region has become one of the factors driving the growth of JE vaccine market in tropical region.
JE vaccine can be used for children and adults above 2 months of age. Vaccination is recommended for travelers to Asia who meet any of the following conditions: intend to stay in JE-prone areas for at least 1 month; will travel for less than 1 month but will travel to rural areas and spend most of their time outdoors; are traveling to JE-prone areas; or are uncertain about their trip. Laboratory workers who may be at risk of exposure to JE virus should also receive the vaccine. Thus, increased safety awareness will further contribute to the development of the demand for JE vaccine.
Region Overview:
Asia Pacific had the highest growth rate of all regions.
Company Overview:
Chengdu institute of biologica is one of the major players operating in the Japanese Encephalitis (JE) Vaccine market, holding a share of 14.95% in 2020.
Chengdu Institute of Biology (CIB), founded in 1958, is a public academic institution directly under the Chinese Academy of Sciences (CAS). As one of the first selected units for Knowledge Innovation Program of CAS, CIB has been dedicated in research in term of biodiversity conservation and sustainable uses of bioresources, and is scientific foundation, technical support and decision-making basis for ecological environment construction and biodiversity conservation of the upper reaches of Yangtze River as well as formation and promotion of strategic emerging biological industry.
CIB has developed substantial and solid cooperation with universities and scientific research institution in over 20 countries, e.g., US, UK, Germany，France and Russia. Strategic partnership with domestic universities, institutions and companies has been established also.
Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers and various vaccines in development, including unique vaccines against Lyme disease, chikungunya and COVID-19.
The Company has operations in Austria, Sweden, the United Kingdom, France, Canada and the US.
Segmentation Overview:
Among different product types, Live Attenuated Vaccine segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Public segment occupied the biggest share from 2017 to 2022.
The Japanese Encephalitis (JE) Vaccine market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types, applications, players, 5 major regions and sub-division of major countries, and sometimes end user, channel, technology, as well as other information individually tailored before order confirmation.
Meticulous research and analysis were conducted during the preparation process of the report. The qualitative and quantitative data were gained and verified through primary and secondary sources, which include but not limited to Magazines, Press Releases, Paid Databases, Maia Data Center, National Customs, Annual Reports, Public Databases, Expert interviews, etc. Besides, primary sources include extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs, and marketing executives, downstream distributors, as well as end-clients.
In this report, the historical period starts from 2018 to 2022, and the forecast period ranges from 2023 to 2028. The facts and data are demonstrated by tables, graphs, pie charts, and other pictorial representations, which enhances the effective visual representation and decision-making capabilities for business strategy.
Key Companies in the global Japanese Encephalitis (JE) Vaccine market covered in Chapter 4:
Liaoning Chengda
Sanofi
Valneva
Chengdu institute of biologica
Biological E. Limited
Bharat Biotech
Wuhan Institute of Biological
In Chapter 12 and Chapter 14.1, on the basis of types, the Japanese Encephalitis (JE) Vaccine market from 2018 to 2028 is primarily split into:
Inactivated Vaccine
Live Attenuated Vaccine
In Chapter 13 and Chapter 14.2, on the basis of the Downstream Industry, the Japanese Encephalitis (JE) Vaccine market from 2018 to 2028 covers:
Public
Private
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, history and forecast (2018-2028) of the following regions are covered in Chapters 6, 7, 8, 9, 10, 11, 15:
North America (United States, Canada, Mexico)
Europe (Germany, United Kingdom, France, Italy, Spain)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina)
Middle East & Africa (Saudi Arabia, UAE, South Africa)
Outline:
Chapter 1 begins with the Japanese Encephalitis (JE) Vaccine market scope and definition, product segment introduction, global overall market size, as well as market dynamics scenarios such as opportunities, challenges, and industry development trends under inflation. It offers a high-level view of the current state of the Japanese Encephalitis (JE) Vaccine market and its likely evolution in the short to mid-term and long term.
Chapter 2 provides Japanese Encephalitis (JE) Vaccine industry chain analysis, covering raw materials analysis, cost structure, price estimate, and forecast, along with price-impacting factors, downstream channels, and major customers. It aims to help readers to grab insights into product upstream, midstream, and downstream fields.
Chapter 3 depicts Japanese Encephalitis (JE) Vaccine industry competitive analysis regarding market concentration rate, saturation rate, feasibility analysis from new entrants, as well as substitute's status and trends. It indicates the developing space and prospects of the current industry.
Chapter 4 analyzes extensive company profiles, comprising company basic info, product or service profiles, and sales, price, value, gross, and gross margin 2018-2023. It incorporates the Japanese Encephalitis (JE) Vaccine market ranking, benchmarks, and company business portfolio.
Chapter 5 presents trade statistics of import and export volume from 2018-2023, demonstrating domestic and international market comparisons in specific countries.
Chapters 6-10 highlight Japanese Encephalitis (JE) Vaccine market status at the regional and country levels, including 5 major regions of North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The region and country list in the sample is only for reference, and it can be adjusted as required.
Chapter 11 involves geographical market figures of sales, value, market share, and growth rate. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of each specific region.
Chapters 12-13 evaluate the Japanese Encephalitis (JE) Vaccine market based on different types and applications. It focuses on sales and value of 2018-2023 from both vertical and horizontal perspectives.
Chapters 14-15 elaborate on the Japanese Encephalitis (JE) Vaccine market forecast data from 2023-2028, segmented by types and applications, regions, and major countries, helping readers to know future aspects and growth trends.
Chapter 16 ends with an elaboration of data sources and research methodology. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
2022
Japanese encephalitis (JE) is the leading cause of viral encephalitis in many Asian countries. JE virus is a flavivirus associated with dengue, yellow fever and West Nile virus and is transmitted by mosquitoes, causing infection. The virus is transmitted in an enzootic cycle (enzootic cycle) between mosquitoes, pigs, and/or waterfowl. Humans become infected when they are bitten by an infected mosquito. The disease occurs mainly in rural and peri-urban areas.
Japanese encephalitis vaccine is a vaccine that protects against Japanese encephalitis.
Market Opportunities
Since the first discovery of JE vaccines in the 1930s, the JE vaccine industry has evolved from the original vaccine to live attenuated and inactivated vaccines as vaccine technology has advanced. Currently, polyvalent conjugate and combination vaccines are the main technological trends.
Moreover, in addition to the rising awareness of the disease, the increase in travel and tourism is one of the key factors contributing to the growth of the industry. The tropics are the most lucrative market due to high prevalence of JE in the tropics, expansion of government-led national immunization programs, growth in R&D investments, entry of new vaccine manufacturers from countries such as India and China, increase in tourist arrivals, medical tourism, etc. Moreover, increase in pig farms, poultry and mosquito infestation in Asia Pacific region has become one of the factors driving the growth of JE vaccine market in tropical region.
JE vaccine can be used for children and adults above 2 months of age. Vaccination is recommended for travelers to Asia who meet any of the following conditions: intend to stay in JE-prone areas for at least 1 month; will travel for less than 1 month but will travel to rural areas and spend most of their time outdoors; are traveling to JE-prone areas; or are uncertain about their trip. Laboratory workers who may be at risk of exposure to JE virus should also receive the vaccine. Thus, increased safety awareness will further contribute to the development of the demand for JE vaccine.
Region Overview:
Asia Pacific had the highest growth rate of all regions.
Company Overview:
Chengdu institute of biologica is one of the major players operating in the Japanese Encephalitis (JE) Vaccine market, holding a share of 14.95% in 2020.
Chengdu Institute of Biology (CIB), founded in 1958, is a public academic institution directly under the Chinese Academy of Sciences (CAS). As one of the first selected units for Knowledge Innovation Program of CAS, CIB has been dedicated in research in term of biodiversity conservation and sustainable uses of bioresources, and is scientific foundation, technical support and decision-making basis for ecological environment construction and biodiversity conservation of the upper reaches of Yangtze River as well as formation and promotion of strategic emerging biological industry.
CIB has developed substantial and solid cooperation with universities and scientific research institution in over 20 countries, e.g., US, UK, Germany，France and Russia. Strategic partnership with domestic universities, institutions and companies has been established also.
Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers and various vaccines in development, including unique vaccines against Lyme disease, chikungunya and COVID-19.
The Company has operations in Austria, Sweden, the United Kingdom, France, Canada and the US.
Segmentation Overview:
Among different product types, Live Attenuated Vaccine segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Public segment occupied the biggest share from 2017 to 2022.
The Japanese Encephalitis (JE) Vaccine market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types, applications, players, 5 major regions and sub-division of major countries, and sometimes end user, channel, technology, as well as other information individually tailored before order confirmation.
Meticulous research and analysis were conducted during the preparation process of the report. The qualitative and quantitative data were gained and verified through primary and secondary sources, which include but not limited to Magazines, Press Releases, Paid Databases, Maia Data Center, National Customs, Annual Reports, Public Databases, Expert interviews, etc. Besides, primary sources include extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs, and marketing executives, downstream distributors, as well as end-clients.
In this report, the historical period starts from 2018 to 2022, and the forecast period ranges from 2023 to 2028. The facts and data are demonstrated by tables, graphs, pie charts, and other pictorial representations, which enhances the effective visual representation and decision-making capabilities for business strategy.
Key Companies in the global Japanese Encephalitis (JE) Vaccine market covered in Chapter 4:
Liaoning Chengda
Sanofi
Valneva
Chengdu institute of biologica
Biological E. Limited
Bharat Biotech
Wuhan Institute of Biological
In Chapter 12 and Chapter 14.1, on the basis of types, the Japanese Encephalitis (JE) Vaccine market from 2018 to 2028 is primarily split into:
Inactivated Vaccine
Live Attenuated Vaccine
In Chapter 13 and Chapter 14.2, on the basis of the Downstream Industry, the Japanese Encephalitis (JE) Vaccine market from 2018 to 2028 covers:
Public
Private
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, history and forecast (2018-2028) of the following regions are covered in Chapters 6, 7, 8, 9, 10, 11, 15:
North America (United States, Canada, Mexico)
Europe (Germany, United Kingdom, France, Italy, Spain)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina)
Middle East & Africa (Saudi Arabia, UAE, South Africa)
Outline:
Chapter 1 begins with the Japanese Encephalitis (JE) Vaccine market scope and definition, product segment introduction, global overall market size, as well as market dynamics scenarios such as opportunities, challenges, and industry development trends under inflation. It offers a high-level view of the current state of the Japanese Encephalitis (JE) Vaccine market and its likely evolution in the short to mid-term and long term.
Chapter 2 provides Japanese Encephalitis (JE) Vaccine industry chain analysis, covering raw materials analysis, cost structure, price estimate, and forecast, along with price-impacting factors, downstream channels, and major customers. It aims to help readers to grab insights into product upstream, midstream, and downstream fields.
Chapter 3 depicts Japanese Encephalitis (JE) Vaccine industry competitive analysis regarding market concentration rate, saturation rate, feasibility analysis from new entrants, as well as substitute's status and trends. It indicates the developing space and prospects of the current industry.
Chapter 4 analyzes extensive company profiles, comprising company basic info, product or service profiles, and sales, price, value, gross, and gross margin 2018-2023. It incorporates the Japanese Encephalitis (JE) Vaccine market ranking, benchmarks, and company business portfolio.
Chapter 5 presents trade statistics of import and export volume from 2018-2023, demonstrating domestic and international market comparisons in specific countries.
Chapters 6-10 highlight Japanese Encephalitis (JE) Vaccine market status at the regional and country levels, including 5 major regions of North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The region and country list in the sample is only for reference, and it can be adjusted as required.
Chapter 11 involves geographical market figures of sales, value, market share, and growth rate. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of each specific region.
Chapters 12-13 evaluate the Japanese Encephalitis (JE) Vaccine market based on different types and applications. It focuses on sales and value of 2018-2023 from both vertical and horizontal perspectives.
Chapters 14-15 elaborate on the Japanese Encephalitis (JE) Vaccine market forecast data from 2023-2028, segmented by types and applications, regions, and major countries, helping readers to know future aspects and growth trends.
Chapter 16 ends with an elaboration of data sources and research methodology. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
